Key result
Tail vein injection of macrophage membrane-modified biomimetic nanoprobes loaded with PFH and SPIO achieved early identification of myocardial inflammatory sites in an experimental myocarditis model.
Why the study?
Early identification of myocarditis remains challenging, and current guidelines lack a single non-invasive diagnostic method.
Does tail vein injection of MM/NPs loaded with PFH and SPIO allow early identification of myocardial inflammatory sites in an experimental autoimmune myocarditis animal model?
Does tail vein injection of MM/NPs loaded with PFH and SPIO allow early identification of myocardial inflammatory sites in an experimental autoimmune myocarditis animal model?
Macrophage membrane-modified targeted phase-change nanoparticles loaded with PFH and SPIO enable early identification of myocardial inflammation in an experimental autoimmune myocarditis model using multimodal imaging.
Preclinical PLGA-based targeted imaging shows promise for early myocarditis detection; leaves open clinical translation and validation.
Myocarditis is an important public health issue due to the high prevalence of sudden death in adolescents and young adults. Nevertheless, the early identification of myocarditis remains a serious problem for clinicians. There is no single non-invasive method to diagnose myocarditis in the currently available clinical guidelines and consensus. Molecular imaging is an effective approach for accurate diagnosis. Poly(lactic acid-glycolic acid) (PLGA) is considered to be the preferred carrier for molecular imaging because of its biosafety and modifiability. Macrophage membrane-modified biomimetic nanoprobes (MM-NPs) possess low immunogenicity and inflammation-directed chemotaxis capabilities and are repeatedly chosen as materials for targeted diagnosis and treatment of inflammatory diseases. In this study, experimental autoimmune myocarditis (EAM) was used as an animal model of inflammation. Previous studies have confirmed that this model is similar to pathological injury caused by acute myocarditis in humans. In multimodal imaging (US/PA/MRI), a phase-change material (PFH) and superparamagnetic iron oxide (SPIO) are used as imaging substances. Early identification of myocardial inflammatory sites was achieved by the tail vein injection of MM/NPs loaded with PFH and SPIO. This probe is expected to be a powerful tool for clinicians to diagnose myocarditis.
No takes yet. Share an insight, caveat, or question.
Yin et al. (2024) studied Experimental autoimmune myocarditis. Macrophage membrane-modified biomimetic nanoprobes (MM-NPs) loaded with PFH and SPIO was evaluated on Early identification of myocardial inflammatory sites via multimodal imaging (US/PA/MRI). Tail vein injection of macrophage membrane-modified biomimetic nanoprobes loaded with PFH and SPIO achieved early identification of myocardial inflammatory sites in an experimental myocarditis model.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: